Methodology of a phase 2, randomized, double-blind, placebo-controlled, parallel group, dose-ranging, 36-week, multicenter trial to evaluate the efficacy and safety of daxibotulinumtoxinA for injection for the treatment of upper limb spasticity in adults after stroke or traumatic brain injury